HBM Holdings Limited (HKG:2142)

Market Cap	13.17B
Revenue (ttm)	908.35M
Net Income (ttm)	573.61M
Shares Out	839.08M
EPS (ttm)	0.72
PE Ratio	21.70
Forward PE	23.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,693,600
Average Volume	11,034,521
Open	14.50
Previous Close	14.52
Day's Range	14.50 - 15.85
52-Week Range	1.12 - 17.98
Beta	1.86
RSI	58.19
Earnings Date	Nov 27, 2025

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 183
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD